论文部分内容阅读
晚期乳腺癌的治疗至今还是一种姑息性治疗,不能做到根治及治愈。主要治疗的方法有两种:一种是以几种抗癌药进行联合化疗,疗效在50～70％,约1/3患者可达到完全缓解,缓解期约6～8月。另一种是以内分泌药物治疗,疗效一般只有30％左右。但近年来,通过以雌激素受体(ER)测定选择治疗对象,疗效也可提高到50～70％,与联合化疗相仿。而且内分泌治疗的缓解期较长,常达到一年以上,不良反应也比联合化疗少。因此,近年来,晚期乳腺癌的内分泌治疗逐渐受到医学界的重视。
The treatment of advanced breast cancer is still a palliative treatment and cannot be cured or cured. There are two main methods of treatment: One is the combination of several anti-cancer drugs for chemotherapy, the efficacy of 50 to 70%, about 1/3 of patients can achieve complete remission, remission period of about 6 to 8 months. The other is endocrine drug treatment, the efficacy is generally only about 30%. However, in recent years, the efficacy of treatment has been improved to 50-70% by selecting the treatment subject with estrogen receptor (ER) assay, which is similar to that of combination chemotherapy. Moreover, the remission period of endocrine therapy is longer, often reaching more than one year, and adverse reactions are also less than that of combination chemotherapy. Therefore, in recent years, the endocrine treatment of advanced breast cancer has gradually received the attention of the medical community.